Pyxis Oncology Inc (PYXS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $188.98M
Last updated: Nov 17, 2026 at 11:05 AM ET
Pyxis Oncology Inc (PYXS) Competitors
The companies most similar to Pyxis Oncology are Compass Therapeutics (CMPX), PolyPid (PYPD) and Innate Pharma (IPHA). By market cap, Pyxis Oncology ranks 6th of the 13 companies on this page; Prelude Therapeutics (PRLD) is the largest at $275.32M.
Peer Comparison
PYXS's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Pyxis Oncology (PYXS) | $188.98M | N/A | 11.6x | 0.0% | N/A | 0.0% | 0.00% |
| Compass Therapeutics Inc. (CMPX) | $139.35M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| PolyPid (PYPD) | $132.25M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Innate Pharma (IPHA) | $154.15M | N/A | 17.6x | 0.0% | 489.8% | 16.5% | 0.00% |
| Protalix Biotherapeutics Inc (PLX) | $257.17M | 12.1x | 2.9x | 24.3% | N/A | 22.8% | 0.00% |
| Keros Therapeutics Inc (KROS) | $202.13M | N/A | 4.9x | -151.4% | N/A | 180.5% | 0.00% |
| Invivyd Inc. (IVVD) | $171.58M | N/A | 2.9x | -183.9% | N/A | 21.2% | 0.00% |
| Protara Therapeutics Inc (TARA) | $155.77M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Prelude Therapeutics Inc (PRLD) | $275.32M | N/A | 16.3x | -269.7% | N/A | 41.0% | 0.00% |
| NeOnc Technologies Holdings, Inc. Common Stock (NTHI) | $141.66M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| MacroGenics Inc (MGNX) | $140.60M | N/A | 1.2x | -36.6% | -108.7% | -64.8% | 0.00% |
| Greenwich Lifesciences Inc (GLSI) | $219.29M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Rocket Pharmaceuticals Inc (RCKT) | $256.82M | N/A | N/A | 0.0% | -2.3% | 0.0% | 0.00% |
| Peer median | $163.68M | 12.1x | 3.9x | 0.0% | -2.3% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Pyxis Oncology, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Compass Therapeutics Inc. (CMPX) | Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple... | CMPX competitors |
| PolyPid (PYPD) | PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX)... | PYPD competitors |
| Innate Pharma (IPHA) | Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France... | |
| Protalix Biotherapeutics Inc (PLX) | Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its... | PLX competitors |
| Keros Therapeutics Inc (KROS) | Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery... | KROS competitors |
| Invivyd Inc. (IVVD) | Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery... | IVVD competitors |
| Protara Therapeutics Inc (TARA) | Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment... | TARA competitors |
| Prelude Therapeutics Inc (PRLD) | Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized... | PRLD competitors |
| NeOnc Technologies Holdings, Inc. Common Stock (NTHI) | NeOnc Technologies Holdings, Inc. is a pioneering biotechnology firm dedicated to revolutionizing cancer treatment through its advanced immunotherapy... | NTHI competitors |
| MacroGenics Inc (MGNX) | MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. | MGNX competitors |
| Greenwich Lifesciences Inc (GLSI) | Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 /... | GLSI competitors |
| Rocket Pharmaceuticals Inc (RCKT) | Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. | RCKT competitors |
Frequently Asked Questions About PYXS
Who are Pyxis Oncology's main competitors?
The companies most similar to Pyxis Oncology include Compass Therapeutics (CMPX), PolyPid (PYPD), Innate Pharma (IPHA), Protalix Biotherapeutics (PLX) and Keros Therapeutics (KROS), listed from the closest match.
Who is Pyxis Oncology's biggest competitor?
Prelude Therapeutics (PRLD) is the largest of the similar companies at $275.32M; Compass Therapeutics (CMPX) is the closest match by business profile, size, sector and industry.
How does PYXS stock compare with its competitors?
PYXS' P/S is 11.6x against a peer median of 3.9x; its net margin is 0.0% against a peer median of 0.0%.
Which of Pyxis Oncology's competitors pays a higher dividend?
Pyxis Oncology pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Pyxis Oncology bigger than its competitors?
No. Pyxis Oncology is 6th by market cap among the 13 companies on this page; the largest is Prelude Therapeutics (PRLD) at $275.32M.
PYXS pages: Overview, Earnings, Forecast, Financials, Competitors